Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $16.6 million.

  • Biodesix's Cash & Equivalents fell 47.13% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 47.13%. This contributed to the annual value of $26.2 million for FY2024, which is 0.15% down from last year.
  • Per Biodesix's latest filing, its Cash & Equivalents stood at $16.6 million for Q3 2025, which was down 19.90% from $20.7 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Cash & Equivalents registered a high of $56.3 million during Q2 2021, and its lowest value of $11.5 million during Q1 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $20.7 million (2025), whereas its average is $23.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 654.77% in 2021, then tumbled by 70.31% in 2022.
  • Quarterly analysis of 5 years shows Biodesix's Cash & Equivalents stood at $32.7 million in 2021, then soared by 31.72% to $43.1 million in 2022, then tumbled by 39.00% to $26.3 million in 2023, then decreased by 0.15% to $26.2 million in 2024, then tumbled by 47.13% to $16.6 million in 2025.
  • Its Cash & Equivalents was $16.6 million in Q3 2025, compared to $20.7 million in Q2 2025 and $17.6 million in Q1 2025.